What is Dogwood Therapeutics's earnings per share (EPS)?

Dogwood Therapeutics (DWTX) reported diluted earnings per share of $-7.13 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Dogwood Therapeutics Financials

DWTX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Dogwood Therapeutics (DWTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DWTX FY2025 2026-05-15

Dogwood remains a cash-funded R&D enterprise, with capital raises and balance-sheet resets doing more work than operations.

After the prior year's negative equity, shareholders' equity turned positive, yet cash ended FY2025 at only $6.5M. With operating cash outflow at $15.6M, the company was solvent on paper but still externally financed in practice, because its year-end cash covered less than half of one year's operating use.

The spending mix swung back toward development activity, with R&D at $21.9M and SG&A at $6.1M. The prior year showed the opposite pattern, so the cost structure looks more like a research program again than an administration-heavy shell, even though that re-acceleration also widened losses and increased cash needs.

Reported loss ran ahead of cash burn, with net loss at $34.3M versus operating cash outflow of $15.6M. That gap implies earnings were hit by items that did not drain cash immediately, yet financing inflows still had to support the balance because operations supplied none and cash continued to shrink.

Financial Health Signals

Financial health score pending refresh

We are recalculating Dogwood Therapeutics's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Dogwood Therapeutics passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.46x

For every $1 of reported earnings, Dogwood Therapeutics generates $0.46 in operating cash flow (-$15.6M OCF vs -$34.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$28.0M

YoY-128.9%

Dogwood Therapeutics's EBITDA was -$28.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 128.9% from the prior year.

Net Income

-$34.3M

YoY-177.4%

Dogwood Therapeutics reported -$34.3M in net income in fiscal year 2025. This represents a decrease of 177.4% from the prior year.

EPS (Diluted)

$-7.13

Dogwood Therapeutics earned $-7.13 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$6.5M

YoY-56.1%

5Y CAGR-26.2%

Dogwood Therapeutics held $6.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

30M

Dogwood Therapeutics had 30M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-45.7%

5Y CAGR-11.2pp

Dogwood Therapeutics's ROE was -45.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$21.9M

YoY+519.3%

5Y CAGR+157.3%

Dogwood Therapeutics invested $21.9M in research and development in fiscal year 2025. This represents an increase of 519.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

DWTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$21.9M+519.3%	$3.5M+104.3%	$1.7M-78.6%	$8.1M-25.3%	$10.8M+5464.4%	$194K
SG&A Expenses	$6.1M-29.8%	$8.7M+133.8%	$3.7M-12.4%	$4.2M-12.4%	$4.8M-50.6%	$9.8M
Operating Income	-$28.0M-128.7%	-$12.2M-124.5%	-$5.4M+55.8%	-$12.3M+21.3%	-$15.6M-56.3%	-$10.0M
Interest Expense	N/A	N/A	$151K+123.6%	$67K+1089.6%	$6K+101.5%	-$384K
Income Tax	$221K+44055.5%	-$503	N/A	N/A	N/A	N/A
Net Income	-$34.3M-177.4%	-$12.3M-133.2%	-$5.3M+56.8%	-$12.2M+23.3%	-$16.0M-54.3%	-$10.3M
EPS (Diluted)	$-7.13	$-12.52-77.6%	$-7.05	$-1.11+42.2%	$-1.92+8.6%	$-2.10

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.7M	N/A	$14.5M+465.0%	$2.6M+5.5%	$2.4M	N/A	$535K+59.2%	$336K
SG&A Expenses	$2.4M	N/A	$1.3M-4.8%	$1.4M-32.1%	$2.0M	N/A	$1.8M+140.7%	$734K
Operating Income	-$5.1M	N/A	-$15.8M-303.0%	-$3.9M+11.4%	-$4.4M	N/A	-$2.3M-115.1%	-$1.1M
Interest Expense	$77K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.0M	N/A	-$15.7M-313.5%	-$3.8M+65.1%	-$10.9M	N/A	-$2.3M-117.2%	-$1.0M
EPS (Diluted)	$-0.15	N/A	$-8.20-312.1%	$-1.99+76.4%	$-8.45	N/A	$-2.05	$-1.15

DWTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$90.2M-4.4%	$94.3M+2164.1%	$4.2M-50.2%	$8.4M-46.9%	$15.8M-49.9%	$31.5M
Current Assets	$8.4M-49.0%	$16.5M+297.2%	$4.2M-50.2%	$8.4M-46.9%	$15.8M-49.9%	$31.5M
Cash & Equivalents	$6.5M-56.1%	$14.8M+347.6%	$3.3M-52.8%	$7.0M-49.8%	$14.0M-53.0%	$29.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$12.4M+5.0%	$11.8M	N/A	N/A	N/A	N/A
Total Liabilities	$15.3M-85.4%	$104.4M+29026.5%	$359K-65.6%	$1.0M-18.2%	$1.3M-16.7%	$1.5M
Current Liabilities	$3.1M-3.7%	$3.2M+785.9%	$359K-65.6%	$1.0M-18.2%	$1.3M-16.7%	$1.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$74.9M+839.8%	-$10.1M-365.9%	$3.8M-48.0%	$7.3M-49.5%	$14.5M-51.6%	$29.9M
Retained Earnings	-$108.1M-46.4%	-$73.8M-20.1%	-$61.5M-9.4%	-$56.2M-27.9%	-$43.9M-57.1%	-$28.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$95.2M+5.6%	$90.2M-2.0%	$92.0M-4.9%	$96.7M-0.3%	$97.0M+2.8%	$94.3M+4030.4%	$2.3M-37.2%	$3.6M
Current Assets	$15.0M+78.0%	$8.4M-27.7%	$11.7M-20.7%	$14.7M-23.3%	$19.2M+15.8%	$16.5M+624.6%	$2.3M-37.2%	$3.6M
Cash & Equivalents	$13.2M+102.7%	$6.5M-35.6%	$10.1M-24.4%	$13.4M-23.6%	$17.5M+18.1%	$14.8M+627.9%	$2.0M-32.5%	$3.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$12.2M-1.7%	$12.4M+1.6%	$12.2M-2.0%	$12.5M+5.4%	$11.8M+0.1%	$11.8M	N/A	N/A
Total Liabilities	$14.6M-4.5%	$15.3M-82.0%	$84.7M-5.7%	$89.8M-0.1%	$89.9M-13.9%	$104.4M+7729.6%	$1.3M+166.7%	$500K
Current Liabilities	$2.6M-16.3%	$3.1M+17.8%	$2.6M+37.7%	$1.9M-26.9%	$2.6M-18.8%	$3.2M+138.1%	$1.3M+166.7%	$500K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$80.6M+7.6%	$74.9M+931.9%	$7.3M+5.5%	$6.9M-2.9%	$7.1M+170.0%	-$10.1M-1166.4%	$949K-69.7%	$3.1M
Retained Earnings	-$113.1M-4.6%	-$108.1M-3.6%	-$104.3M-17.8%	-$88.6M-4.5%	-$84.7M-14.8%	-$73.8M-11.7%	-$66.1M-3.6%	-$63.8M

DWTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$15.6M-77.7%	-$8.8M-80.5%	-$4.9M+57.5%	-$11.5M+26.9%	-$15.7M-302.8%	-$3.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$3.8M	N/A	N/A	N/A	N/A
Financing Cash Flow	$7.3M-56.4%	$16.7M+1344.5%	$1.2M-74.2%	$4.5M+4700.8%	-$98K-100.3%	$33.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$4.6M-26.1%	-$3.6M-11.1%	-$3.3M+18.7%	-$4.0M+14.0%	-$4.7M+23.6%	-$6.1M-573.7%	-$910K-12.1%	-$812K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$11.3M+34577.5%	$33K	$0+100.0%	-$120K-101.6%	$7.4M-51.9%	$15.3M+21918.2%	-$70K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

DWTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-45.7%	N/A	-139.1%+28.0pp	-167.2%-57.1pp	-110.1%-75.5pp	-34.6%
Return on Assets	-38.0%-24.9pp	-13.1%+114.0pp	-127.1%+19.2pp	-146.3%-45.2pp	-101.2%-68.3pp	-32.9%
Current Ratio	2.76-2.5	5.21-6.4	11.62+3.6	8.02-4.3	12.37-8.2	20.55
Debt-to-Equity	0.20+10.5	-10.31-10.4	0.09-0.0	0.14+0.1	0.09+0.0	0.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-6.2%	N/A	-216.9%-161.6pp	-55.4%+98.8pp	-154.2%	N/A	-240.2%-206.7pp	-33.5%
Return on Assets	-5.2%	N/A	-17.1%-13.2pp	-3.9%+7.3pp	-11.3%	N/A	-99.9%-71.0pp	-28.9%
Current Ratio	5.86+3.1	2.76-1.7	4.49-3.3	7.80+0.4	7.43+2.2	5.21+3.5	1.71-5.6	7.27
Debt-to-Equity	0.18-0.0	0.20-11.5	11.67-1.4	13.06+0.4	12.69+23.0	-10.31-11.7	1.40+1.2	0.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Cyclacel Phar Pr CYCCP

$9.6M

Processa Pharmaceuticals Inc PCSA

$6.3M

Transcode Therapeutics Inc RNAZ

$8.2M

Aprea Therapeutics, Inc. APRE

$9.0M

Aeon Biopharma AEON

$9.4M

Frequently Asked Questions

Is Dogwood Therapeutics profitable?

No, Dogwood Therapeutics (DWTX) reported a net income of -$34.3M in fiscal year 2025.

What is Dogwood Therapeutics's EBITDA?

Dogwood Therapeutics (DWTX) had EBITDA of -$28.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Dogwood Therapeutics's return on equity (ROE)?

Dogwood Therapeutics (DWTX) has a return on equity of -45.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Dogwood Therapeutics's operating cash flow?

Dogwood Therapeutics (DWTX) generated -$15.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Dogwood Therapeutics's total assets?

Dogwood Therapeutics (DWTX) had $90.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Dogwood Therapeutics spend on research and development?

Dogwood Therapeutics (DWTX) invested $21.9M in research and development during fiscal year 2025.

How many shares does Dogwood Therapeutics have outstanding?

Dogwood Therapeutics (DWTX) had 30M shares outstanding as of fiscal year 2025.

What is Dogwood Therapeutics's current ratio?

Dogwood Therapeutics (DWTX) had a current ratio of 2.76 as of fiscal year 2025, which is generally considered healthy.

What is Dogwood Therapeutics's debt-to-equity ratio?

Dogwood Therapeutics (DWTX) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Dogwood Therapeutics's return on assets (ROA)?

Dogwood Therapeutics (DWTX) had a return on assets of -38.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Dogwood Therapeutics's cash runway?

Based on fiscal year 2025 data, Dogwood Therapeutics (DWTX) had $6.5M in cash against an annual operating cash burn of $15.6M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Dogwood Therapeutics's Piotroski F-Score?

Dogwood Therapeutics (DWTX) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Dogwood Therapeutics's earnings high quality?

Dogwood Therapeutics (DWTX) has an earnings quality ratio of 0.46x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.